ASH Annual Meeting and Exposition | Conference

Sabatolimab Demonstrates Durable Clinical Benefits in Patients With AML, High-Risk MDS

December 14th 2021

Sabatolimab, an investigational TIM-3 monoclonal antibody, induced a median duration of response greater than 1 year for patients with very high/high-risk myelodysplastic syndrome and acute myeloid leukemia when used in combination with hypomethylating agents.

Link Between Elevated WBC and Thrombotic Events in Polycythemia Vera Highlights Potential Prevention Strategy

December 14th 2021

Patients with polycythemia vera who have controlled hematocrit levels, but elevated white blood counts are at an increased risk of thrombotic events, according to a presentation of the REVEAL study.

YTB323 Shows Encouraging Efficacy in Relapsed/Refractory DLBCL

December 14th 2021

YTB323, a novel, autologous CD19-directed CAR-T cell therapy, displayed a favorable safety profile and efficacy across multiple dose levels in adult patients with relapsed/refractory diffuse large b-cell lymphoma.

Venetoclax-Based Triplet Continues to Confer Tolerable Safety, Deep Responses in t(11;14) Relapsed/Refractory Multiple Myeloma

December 14th 2021

Venetoclax at either 400 mg or 800 mg plus daratumumab and dexamethasone elicited deep durable responses and was associated with a tolerable safety profile in patients with t(11;14) relapsed/refractory multiple myeloma.

Interventions Needed to Improve QoL, Reduce Psychological Distress in Patients With Myeloma

December 14th 2021

Prognostic awareness was associated with higher rates of psychosocial distress and symptom burden, and lower quality of life in patients with multiple myeloma.

Lower Doses of Selinexor Plus Bortezomib and Dexamethasone Show Best Efficacy and Safety in Myeloma

December 14th 2021

Lower 60mg and 40mg doses of Selinexor in combination with bortezomib and dexamethasone demonstrated improved efficacy and safety vs a 100mg dose for patients with relapsed or refractory multiple myeloma.

Ibrutinib Plus Venetoclax Induces Lower MRD Rate Vs FCR in Previously Untreated CLL

December 14th 2021

The combination of ibrutinib and venetoclax led to a lower rate of minimal residual disease compared with fludarabine, cyclophosphamide, and rituximab in patients with treatment-naïve chronic lymphocytic leukemia, according to preliminary findings from the phase 2 ERADIC trial.

Frontline Axi-Cel Elicits Durable Responses in High-Risk LBCL

December 14th 2021

Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.

Polatuzumab Vedotin Plus R-CHP Improves PFS in Newly Diagnosed DLBCL

December 14th 2021

The addition of polatuzumab vedotin-piiq to R-CHP led to a 27% reduction in the risk of progression or death vs R-CHOP in patients with previously untreated, intermediate- and high-risk diffuse large B-cell lymphoma.

Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

December 14th 2021

As second-line treatment, tisagenlecleucel failed to demonstrate an event-free survival advantage compared with standard of care platinum-based chemotherapy followed by autologous stem cell transplant or additional chemotherapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Dr. Biran on the Results of an Arm of the STOMP Trial in R/R Multiple Myeloma

December 13th 2021

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Dr. Ghia on the Results From the 2-Year Follow-Up of the CAPTIVATE Study in CLL

December 13th 2021

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

Ibrutinib Plus FCR Shows Encouraging Activity as Time-Limited Option for Younger Patients With CLL

December 13th 2021

The addition of ibrutinib to fludarabine, cyclophosphamide, and rituximab resulted in a higher rate of complete responses with bone marrow undetectable minimal residual disease in younger, fit patients with chronic lymphocytic leukemia.

Cilta-Cel Continues to Impress With Durable and Deep Responses in Relapsed/Refractory Multiple Myeloma

December 13th 2021

Ciltacabtagene autoleucel elicited a 97.9% objective response rate and an 82.5% stringent complete response rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up.

Acalabrutinib Improves PFS, Safety in Untreated CLL

December 13th 2021

Acalabrutinib, with or without obinutuzumab, induced a significant efficacy benefit for patients with treatment-naïve chronic lymphocytic leukemia compared with ibrutinib or venetoclax plus obinutuzumab, according to findings presented during the 63rd ASH Annual Meeting and Exposition.

Higher-Dosed Selinexor Plus Pomalidomide and Dexamethasone Demonstrates Efficacy in Relapsed/Refractory Multiple Myeloma

December 13th 2021

The 60mg phase 2 dose of selinexor plus pomalidomide and dexamethasone produced more durable and deep responses than the lesser selinexor dose for relapsed or refractory multiple myeloma.

Duvelisib plus Romidepsin Displays Activity in R/R PTCL

December 13th 2021

The combination of duvelisib plus romidepsin was shown to be highly active in patients with relapsed/peripheral T-cell lymphoma, according to final results from the dose expansion stage of a phase 1 trial.

Ibrutinib-Based Combos Improve PFS Vs Standard BR in Elderly Patients With CLL

December 13th 2021

Ibrutinib-containing combinations demonstrated continued progression-free survival benefit compared with standard bendamustine plus rituximab in elderly patients with previously untreated chronic lymphocytic leukemia.

Real-World Evidence Supports Axi-Cel in Previously Excluded LBCL Populations

December 13th 2021

Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma; however, adverse events were more common in some of these populations and ECOG performance status ≥2 was associated with worse outcomes and more adverse events, according to a large real-world study presented at the 2021 ASH Annual Meeting.

Cilta-Cel Produces Deep Responses as Second-Line Treatment in Early Relapse Myeloma

December 13th 2021

A single infusion of ciltacabtagene autoleucel produced early and deep responses and encouraging minimal residue disease negativity in patients with multiple myeloma who experienced early clinical relapse following initial therapy.